Our platform for clinicians, researchers, registries and transplant centers

Information and services for healthcare professionals working in hematopoietic stem cell transplantation

At DKMS, we continuously work to improve patients’ situation with blood cancer and other life-threatening blood disorders around the world. Driven by innovation, we aim to provide the best possible services for medical and healthcare professionals. On this platform, you will find comprehensive information on accessing our services, research and resources as well as grants and programs we offer to support your work.

Center of innovation

Find out more about our mission, our departments, our network and our services, as well as the research we conduct to improve the outcome of hematopoietic stem cell transplantation for patients.

Our Network

Recent Publications

Latest News & Stories

Read more about our scientific studies as well as our programs, grants and awards.
DKMS honors Professor Carl June for his groundbreaking work
Foundation DKMS Stiftung Leben Spenden honors Professor Carl H. June for his outstanding achievements in cancer immunology with the DKMS Mechtild Harf Science Award 2023. Throughout his distinguished career, the physician-scientist has made significant contributions to the field of immunology, including his pioneering work on the use of T cells in cancer. He was instrumental in the development of chimeric antigen receptor (CAR)-T cell therapy, which has proven remarkably effective in treating patients with relapsed and refractory leukemia and lymphoma. Moreover, his work has not only created a paradigm shift in the treatment of blood cancers, but it also has the potential to improve treatment options for solid cancers, chronic infections, and autoimmune diseases in the future. Already, numerous preclinical and clinical trials are underway, which hold great promise not only for the scientific community, but most importantly for all affected patients and their families.
First DKMS clinical trial has practice-changing results for patients with AML
In acute myeloid leukemia (AML), standard of care is to attempt a complete remission before stem cell transplantation. This imperative is now being challenged by the results of the first ever completed clinical trial facilitated and organized by DKMS. The trial was supported by the Study Alliance Leukemia (SAL), the Cooperative German Transplant Study Group, and the Gert and Susanna Mayer Foundation. The results of this trial suggest that adult patients that are dealing with relapse or refractory AML should receive stem cell transplantation as soon as possible. Contrary to earlier assumptions, achieving complete remission prior to transplantation does not increase the overall chances for life but even unnecessarily prolongs chemotherapy, associated side effects, and hospitalization. This important conclusion was reached by the researchers at the University Hospital Carl Gustav Carus Dresden, the National Center for Tumor Diseases Dresden (NCT/UCC), and the University Hospital Münster (Germany). Prof. Dr. Schetelig, Head of the Department of Stem Cell Transplantation at the University Hospital Dresden and Head of the DKMS Clinical Trials Unit, presented the results on December 11 at the world's largest hematology congress - the annual meeting of the American Society of Hematology (ASH) - in New Orleans, USA.
An updated version of this page is available.